Access & Pricing

Drug pricing and access dominate policy debate with multiple post-IRA implementation milestones. The session covers IRA Medicare negotiation outcomes (first 10 drugs), EU Joint Clinical Assessment (JCA) implementation, NICE methods and evidence requirements, outcome-based contracts for cell/gene therapy, patient assistance programmes post-IRA, and global access frameworks. Discussion addresses ICER value frameworks, the comparison of US vs EU vs Asian pricing, orphan drug pricing, out-of-pocket caps, international reference pricing debate, and emerging value-based contracting for high-cost therapies.